Cogent Biosciences, Inc. revenue

Cogent Biosciences, Inc.'s revenue was $7.9m in fiscal 2020, down 65.0% on the year before. Since fiscal 2017 ($8.4m) it has grown at a compound -2.0% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cogent Biosciences, Inc.: revenue history, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020
Revenue	8	10	22	8
Growth on the year before	—	+16.4%	+131.1%	−65.0%

US$ millions unless shown otherwise. Fiscal quarters.

Cogent Biosciences, Inc.: revenue history, quarterly
Quarter	2019 Q1Mar 2019	2019 Q2Jun 2019	2019 Q3Sept 2019	2019 Q4Dec 2019	2020 Q1Mar 2020	2020 Q2Jun 2020	2020 Q3Sept 2020	2020 Q4Dec 2020
Revenue	3	3	1	15	7	1	0	0
Growth on the same quarter a year before	—	—	—	—	+130.3%	−83.2%	−69.4%	−100.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Cogent Biosciences, Inc.	$7.9m	-65.0%	-2.0%
Coya Therapeutics, Inc.	$8.0m	1793.8%	—
Adagene Inc.	$7.7m	7332.8%	—
Aclaris Therapeutics, Inc.	$8.2m	-51.0%	-35.9%
Roivant Sciences Ltd.	$7.5m	-67.6%	-46.4%
Evaxion A/s	$7.5m	125.1%	—

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cogent Biosciences, Inc.